Apple Intelligence China Approval Lifts Alibaba and Baidu Shares 
SpaceX Stock Falls Below IPO Price as Investors Weigh Losses and Lockup Expiry 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
NY Times Challenges Trump Administration Subpoenas Over Air Force One Report 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs 
Uber to Acquire Delivery Hero in $14.8 Billion Deal to Expand Global Food Delivery Business 
Stripe, Advent Offer Over $53 Billion to Acquire PayPal in Major Fintech Deal 
Jamie Dimon Warns Anthropic's Mythos AI Poses National Security Risks 
BHP Q4 Iron Ore Output Rebounds as Copper Prices Boost Revenue 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Nvidia Partners With Fanuc and Yaskawa to Accelerate AI Robotics in Japan 
xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
TUCSON, Ariz., Jan. 27, 2016 -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that its management will be presenting at the Leerink Partners 5th Annual Global Healthcare Conference on Wednesday, February 10, 2016 in New York.
HTG management is scheduled to present at 8:25 a.m. ET. A live audio webcast of the presentation can be accessed by visiting the “Investors” section of HTG’s website at: http://www.htgmolecular.com. The webcast will be available on HTG's website for 90 days following the completion of the presentation.
About HTG Molecular Diagnostics:
Headquartered in Tucson, Arizona, HTG’s mission is to empower precision medicine at the local level. In 2013 the company commercialized its HTG Edge instrument platform and a portfolio of RNA assays that leverage HTG's proprietary nuclease protection chemistry. HTG’s product offerings have since expanded to include its HTG EdgeSeq product line, which automates sample and targeted library preparation for next-generation sequencing. Additional information is available at www.htgmolecular.com.
Contact: Westwicke Partners Jamar Ismail Phone: 415-513-1282 Email: [email protected] TJ Johnson President / CEO HTG Molecular Diagnostics Phone: 520-547-2827 x130 Email: [email protected]
